Emerging insights into mesenchymal stem cells and exosome-based therapies for liver injury
Hepatic ischemia-reperfusion injury, fatty liver, liver fibrosis, liver peroxidative injury, and drug-induced liver injury are among the most common liver diseases. Mesenchymal stem cells (MSCs) possess multi-lineage differentiation potential and immunomodulatory functions. In the treatment of live...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2025-05-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/12144 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hepatic ischemia-reperfusion injury, fatty liver, liver fibrosis, liver peroxidative injury, and drug-induced liver injury are among the most common liver diseases. Mesenchymal stem cells (MSCs) possess multi-lineage differentiation potential and immunomodulatory functions. In the treatment of liver injury, MSCs can promote repair through homing effects, direct differentiation into hepatocyte-like cells (HLCs), immunomodulation, and anti-fibrotic mechanisms. Clinically, MSCs contribute to liver injury repair either directly or indirectly via the secretion of exosomes. Beyond their reparative role, MSC-derived exosomes can also serve as molecular biomarkers for the diagnosis and prognosis of liver diseases [1]. Establishing higher-quality standards, robust auditing and evaluation systems, and conducting deeper mechanistic studies are essential prerequisites for the future clinical application of MSCs in the treatment of liver diseases.
|
|---|---|
| ISSN: | 2831-0896 2831-090X |